The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Eiu-104101: A first-in-human phase 1a/1b study of EVOLVE104, a trispecific CD3×CD2×ULBP2/5/6 T-cell engager, in advanced urothelial and squamous cell carcinomas.
 
Tony Fiorino
Employment - EvolveImmune Therapeutics
Leadership - EvolveImmune Therapeutics
Stock and Other Ownership Interests - EvolveImmune Therapeutics
Consulting or Advisory Role - C4 Therapeutics; Catalyst Clinical Research; Nova Anchora; Precision Neuroscience
Patents, Royalties, Other Intellectual Property - EvolveImmune Therapeutics; Zentalis
Expert Testimony - Confidential pharmaceutical company
 
Manish Sharma
Stock and Other Ownership Interests - Abbott Laboratories; Abbvie; Amgen; Bristol-Myers Squibb; Gilead Sciences; Johnson & Johnson/Janssen; Lilly; Merck; Pfizer; Regeneron; Vertex
Consulting or Advisory Role - AADi; Enlaza Therapeutics; Pliant; Whitehawk Therapeutics
Research Funding - Abbvie (Inst); Adcentrx Therapeutics (Inst); Alkermes (Inst); ALX Oncology (Inst); Arcus Biosciences (Inst); Artios (Inst); Arvinas (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); BioNTech SE (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Bolt Biotherapeutics (Inst); Boundless Bio Therapeutics (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Circle Pharma (Inst); Compugen (Inst); Context Therapeutics (Inst); Cullinan Oncology (Inst); Daiichi Sankyo/UCB Japan (Inst); Day One Biopharmaceuticals (Inst); Debiopharm Group (Inst); Deciphera (Inst); EvolveImmune Therapeutics (Inst); Exelixis (Inst); Exscientia (Inst); FoRx Therapeutics (Inst); Genentech/Roche (Inst); Genmab (Inst); Gilead Sciences (Inst); GlaxoSmithKline/Tesaro (Inst); Halda Therapeutics (Inst); Helsinn Therapeutics (Inst); Iambic Therapeutics (Inst); IDEAYA Biosciences (Inst); Ikena Oncology (Inst); Incyte (Inst); InhibRx (Inst); Ipsen (Inst); Johnson & Johnson/Janssen (Inst); Johnson & Johnson/Janssen (Inst); KLUS Pharma (Inst); Kumquat Biosciences (Inst); Macrogenics (Inst); Mbrace Therapeutics (Inst); MediLink Therapeutics (Inst); Menarini Group (Inst); Merck (Inst); Mirati Therapeutics (Inst); Mitsubishi Tanabe Pharma (Inst); Moderna Therapeutics (Inst); Monte Rosa Therapeutics (Inst); NGM Biopharmaceuticals (Inst); NiKang Therapeutics (Inst); Olema Pharmaceuticals (Inst); Opna Bio (Inst); Pfizer (Inst); Pliant (Inst); Quanta Therapeutics (Inst); Regeneron (Inst); Repare Therapeutics (Inst); Seagen (Inst); Takeda (Inst); Third Arc Bio (Inst); Treeline Biosciences (Inst); VelaVigo Bio (Inst); Vividion Therapeutics (Inst); Zymeworks (Inst)
 
Meredith McKean
Consulting or Advisory Role - Abbvie (Inst); Bristol-Myers Squibb (Inst); Castle Biosciences (Inst); Daiichi Sankyo (Inst); IDEAYA Biosciences (Inst); IQvia (Inst); Merck (Inst); Moderna Therapeutics (Inst); Pfizer (Inst); Pierre Fabre (Inst); Regeneron (Inst); Revolution Medicines (Inst)
Research Funding - Arcus Biosciences (Inst); Aulos Bioscience (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); BioNTech (Inst); Boehringer Ingelheim (Inst); C4 Therapeutics (Inst); Daiichi Sankyo (Inst); Dragonfly Therapeutics (Inst); Erasca, Inc (Inst); GenVivo (Inst); Gilead Sciences (Inst); IDEAYA Biosciences (Inst); Ikena Oncology (Inst); immatics (Inst); Immunocore (Inst); Iovance Biotherapeutics (Inst); Jazz Pharmaceuticals (Inst); Kezar Life Sciences (Inst); Krystal Biotech (Inst); Merck (Inst); Moderna Therapeutics (Inst); Nested Therapeutics (Inst); Novartis (Inst); NucMito Pharmaceuticals (Inst); OncoC4 (Inst); Pfizer (Inst); Pierre Fabre (Inst); Prelude Therapeutics (Inst); Regeneron (Inst); Repimune (Inst); Sapience Therapeutics (Inst); Synthorx (Inst); Teva (Inst); TScan Therapeutics (Inst)
 
Jacqueline Brown
Honoraria - Curio Science; DAVA Oncology
Consulting or Advisory Role - AstraZeneca; AstraZeneca; EMD Serono; Exelixis; Pfizer; Xencor
Research Funding - Duality Biologics; Hookipa Pharma (Inst); Loxo/Lilly (Inst); Macrogenics; Medicenna (Inst); Merck (Inst); Novartis (Inst); Pliant; Surface Oncology (Inst); Xencor (Inst)
 
Jacob Thomas
Consulting or Advisory Role - Conjupro Biotherapeutics; Kura Oncology
 
Thomas Marron
Consulting or Advisory Role - Abbvie; Abdera Thereapeutics; AN2; Arrowhead Pharmaceuticals; Astellas Pharma; Avammune; Boehringer Ingelheim; Caris Life Sciences; EMD Serono; Geneos; Merck; Natures Toolbox; Replimune; Storm Therapeutics; Tatum Bioscience
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Regeneron (Inst)
Patents, Royalties, Other Intellectual Property - Patent on the combined use of IL4 blockade and PD-1 blockade. (Inst); Patient on the neoadjuvant use of cemiplimab for the treatment of HCC
 
Shaun O'Brien
Employment - Bristol-Myers Squibb; EvolveImmune Therapeutics
Stock and Other Ownership Interests - Bristol-Myers Squibb; EvolveImmune Therapeutics
 
Xiaowei Guan
Employment - Kinnate Biopharma; Mineralys Therapeutics
Consulting or Advisory Role - EvolveImmune Therapeutics
 
Astha Bhatia
Employment - EvolveImmune Therapeutics; Stemline Therapeutics; Zentalis
Stock and Other Ownership Interests - EvolveImmune Therapeutics
 
Keri Urwin
Consulting or Advisory Role - Ajax Therapeutics; Extend Bio; Kanvas Biosciences; Phylaxis; Prolium; Proniras; Yarrow
 
Oksana Sergeeva
Employment - EvolveImmune Therapeutics
Stock and Other Ownership Interests - EvolveImmune Therapeutics
 
Jay Fine
Employment - EvolveImmune Therapeutics
Stock and Other Ownership Interests - EvolveImmune Therapeutics; Johnson & Johnson; Merck
Consulting or Advisory Role - Empress Therapeutics; Halda Therapeutics
Patents, Royalties, Other Intellectual Property - EvolveImmune Therapeutics
 
Alexander Spira
Leadership - Next Oncology (Inst)
Honoraria - Abbvie; Abbvie; Abbvie; Amgen; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Janssen Oncology; Lilly; Merck; Novartis; Prelude Therapeutics; Takeda
Consulting or Advisory Role - Amgen; ArriVent Biopharma; AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Black Diamond Therapeutics; Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); crispr therapeutics; Daiichi Sankyo/Astra Zeneca; GlaxoSmithKline; Gritstone Bio; Gritstone Bio; incyte; Janssen Research & Development; Jazz Pharmaceuticals; Lilly; Merck (Inst); Mersana; Mirati Therapeutics; Novartis; Regeneron; Revolution Medicines; Sanofi; Sanofi; Synthekine; Takeda
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); ADC Therapeutics (Inst); Alkermes (Inst); Amgen (Inst); ArriVent Biopharma (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); Janssen Oncology (Inst); LAM Therapeutics; lepu biopharma (Inst); Lilly (Inst); Loxo (Inst); Loxo (Inst); Macrogenics (Inst); Medikine (Inst); MedImmune (Inst); mersana (Inst); nalo therapeutics (Inst); Novartis (Inst); Plexxikon (Inst); Prelude Therapeutics (Inst); Regeneron (Inst); Revolution Medicines (Inst); Revolution Medicines (Inst); Roche (Inst); Rubius Therapeutics (Inst); Scorpion Therapeutics (Inst); Synthekine (Inst); Synthekine (Inst); Takeda (Inst); Tango Therapeutics (Inst)